多囊卵巢综合征诊断分型与候选基因研究进展

吕欣璐; 刘瑞; 耿珊

doi:10.11659/jjssx.04E023028

您当前的位置：

首页 >

文章列表页 >

多囊卵巢综合征诊断分型与候选基因研究进展

综述 | 更新时间：2023-12-13

- 多囊卵巢综合征诊断分型与候选基因研究进展
- Research progress of diagnostic classification and candidate genes of polycystic ovary syndrome
- 局解手术学杂志 2023年32卷第12期页码：1100-1104
- 作者机构：
  
  1.重庆市大足区人民医院内分泌科，重庆 402360
  2.重庆医科大学附属第二医院肿瘤科，重庆 400010
- 作者简介：
  
  耿珊，E-mail：83612914@qq.com
- 基金信息：
  
  国家自然科学基金(82170816);中国博士后基金面上项目(2020M683263);重庆市自然科学基金面上项目(cstc2021jcyj-msxmX0353)
- DOI：10.11659/jjssx.04E023028
  中图分类号： R588.6
- 纸质出版日期：2023-12-25，
  
  收稿日期：2022-04-08，
扫描看全文
吕欣璐,刘瑞,耿珊.多囊卵巢综合征诊断分型与候选基因研究进展[J].局解手术学杂志,2023,32(12):1100-1104.

LYU Xin-lu,LIU Rui,GENG Shan.Research progress of diagnostic classification and candidate genes of polycystic ovary syndrome[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2023,32(12):1100-1104.
吕欣璐,刘瑞,耿珊.多囊卵巢综合征诊断分型与候选基因研究进展[J].局解手术学杂志,2023,32(12):1100-1104. DOI： 10.11659/jjssx.04E023028.

LYU Xin-lu,LIU Rui,GENG Shan.Research progress of diagnostic classification and candidate genes of polycystic ovary syndrome[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2023,32(12):1100-1104. DOI： 10.11659/jjssx.04E023028.

摘要

多囊卵巢综合征（PCOS）是一种常见的内分泌疾病，常导致不孕。其发病机制较为复杂，涉及多个器官（下丘脑和卵巢等），同时还涉及遗传因素，因此临床表现及治疗效果存在极大的个体差异。精确的PCOS诊断分型有利于PCOS的个性化治疗和长期管理。本文探讨了PCOS患者不同的临床特征、生化特点以及代谢并发症与基因多态性之间的关系，回顾了与PCOS相关基因的研究进展，以期为PCOS的病理生理学机制提供新的解读，并为PCOS基因诊治提供新思路。

Abstract

Polycystic ovary syndrome （PCOS） is a common endocrine disease that often leads to infertility. Its pathogenesis is relatively

complex， involving multiple organs （hypothalamus and ovary， etc.）， as well as genetic factors. Therefore， there are significant individual differences in clinical manifestations and treatment effects. Precise diagnostic and classification of PCOS is beneficial for personalized

treatment and long-term management of PCOS. This paper discusses the relationship between diverse clinical features， biochemical

characteristics， metabolic complications and gene polymorphisms in PCOS patients， and reviews the research progress on genes associated with PCOS， in order to provide a new interpretation for the pathophysiology mechanism of PCOS and a new idea for the diagnosis and treatment of PCOS gene.

关键词

多囊卵巢综合征基因多态性肥胖胰岛素抵抗

Keywords

polycystic ovary syndromegenetic polymorphismobesityinsulin resistance

references

Rakic D，Jakovljevic V，Jovic N，et al.The potential of SGLT-2 inhibitors in the treatment of polycystic ovary syndrome：the current status and future perspectives［J］.Biomedicines，2023，11（4）：998.doi：10.3390/biomedicines11040998http://dx.doi.org/10.3390/biomedicines11040998.

Azizi Kutenaee M，Amirjani S，Asemi Z，et al.The impact of depression，self-esteem，and body image on sleep quality in patients with PCOS：a cross-sectional study［J］.Sleep Breath，2020，24（3）：1027-1034.doi：10.1007/s11325-019-01946-9http://dx.doi.org/10.1007/s11325-019-01946-9.

Kahsar-Miller M，Azziz R. The development of the polycystic ovary syndrome： family history as a risk factor［J］.Trends Endocrinol Metab，1998，9（2）：55-58. doi：10.1016/s1043-2760（98）00021-6http://dx.doi.org/10.1016/s1043-2760（98）00021-6.

Diamanti-Kandarakis E，Kandarakis H，Legro RS. The role of genes and environment in the etiology of PCOS［J］.Endocrine，2006，30（1）：19-26.doi：10.1385/endo：30：1：19http://dx.doi.org/10.1385/endo：30：1：19.

Dewailly D，Barbotin AL，Dumont A，et al.Role of anti-Müllerian hormone in the pathogenesis of polycystic ovary syndrome［J］.Front Endocrinol （Lausanne），2020，11：641.doi：10.3389/fendo.2020. 00641http://dx.doi.org/10.3389/fendo.2020.00641.

Łebkowska A，Adamska A，Karczewska-Kupczewska M， et al. Serum anti-Müllerian hormone concentration in women with polycystic ovary syndrome and type 1 diabetes mellitus［J］.Metabolism，2016，65（5）：804-811.doi：10.1016/j.metabol.2016.02.005http://dx.doi.org/10.1016/j.metabol.2016.02.005.

Piouka A，Farmakiotis D，Katsikis I，et al.Anti-Müllerian hormone levels reflect severity of PCOS but are negatively influenced by obesity： relationship with increased luteinizing hormone levels［J］. Am J Physiol Endocrinol Metab，2009，296 （2）：E238-E243.doi：10.1152/ajpendo.90684.2008http://dx.doi.org/10.1152/ajpendo.90684.2008.

Sivanandy MS，Ha SK.The role of serum anti-Mullerian hormone measurement in the diagnosis of polycystic ovary syndrome［J］.Diagnostics （Basel），2023，13（5）：907.doi：10.3390/diagnostics130 50907http://dx.doi.org/10.3390/diagnostics13050907.

Joham AE，Norman RJ，Stener-Victorin E，et al.Polycystic ovary syndrome［J］.Lancet Diabetes Endocrinol，2022，10（9）：668-680.doi：10.1016/S2213-8587（22）00163-2http://dx.doi.org/10.1016/S2213-8587（22）00163-2.

Carmina E.Variations in the expression of the polycystic ovary syndrome phenotype［M］. Humana Press eBooks，2008：123-132. doi：10.1007/978-1-59745-108-68http://dx.doi.org/10.1007/978-1-59745-108-68.

Belenkaia LV，Lazareva LM，Walker W，et al.Criteria，phenotypes and prevalence of polycystic ovary syndrome［J］.Minerva Ginecol，2019，71（3）：211-223.doi：10.23736/S0026-4784.19.04404-6http://dx.doi.org/10.23736/S0026-4784.19.04404-6.

Cebeci F，Onsun N，Mert M.Insulin resistance in women with hirsutism［J］.Arch Med Sci，2012，8（2）：342-346.doi：10.5114/aoms.2012.28563http://dx.doi.org/10.5114/aoms.2012.28563.

Cho LW，Kilpatrick ES，Keevil BG，et al.Insulin resistance variability in women with anovulatory and ovulatory polycystic ovary syndrome， and normal controls［J］.Horm Metab Res，2011，43 （2）：141-145.doi：10.1055/s-0030-1270450http://dx.doi.org/10.1055/s-0030-1270450.

Guastella E，Longo RA，Carmina E.Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes［J］.Fertil Steril，2010，94（6）：2197-2201.doi：10.1016/j.fertnstert. 2010. 02.014http://dx.doi.org/10.1016/j.fertnstert.2010.02.014.

Arya S，Hansen KR，Peck JD，et al.Metabolic syndrome in obesity：treatment success and adverse pregnancy outcomes with ovulation induction in polycystic ovary syndrome［J］.Am J Obstet Gynecol，2021，225（3）：280.e1-280.e11.doi：10.1016/j.ajog.2021.03.048http://dx.doi.org/10.1016/j.ajog.2021.03.048.

Carmina E，Lobo RA.Comparing lean and obese PCOS in different PCOS phenotypes：evidence that the body weight is more important than the rotterdam phenotype in influencing the metabolic status［J］.Diagnostics （Basel），2022，12（10）：2313.doi：10.3390/diagnostics12102313http://dx.doi.org/10.3390/diagnostics12102313.

Zhao Y，Ruan X，Mueck AO.Clinical and laboratory indicators of polycystic ovary syndrome in Chinese Han nationality with different Rotterdam criteria-based phenotypes［J］.Gynecol Endocrinol，2016，32（2）：151-156.doi：10.3109/09513590.2015.1107895http://dx.doi.org/10.3109/09513590.2015.1107895.

Zhang X，Miao H，Zhou J，et al.Association between preconception anti-androgen therapy and pregnancy outcomes of patients with PCOS：a prospective cohort study［J］.Front Endocrinol （Lausanne），2023，14：1109861.doi：10.3389/fendo.2023.1109861http://dx.doi.org/10.3389/fendo.2023.1109861.

Jamil AS，Alalaf SK，Al-Tawil NG，et al.Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria［J］.Arch Gynecol Obstet，2016，293（2）：447-456.doi：10.1007/s00404-015-3889-5http://dx.doi.org/10.1007/s00404-015-3889-5.

Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group.Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome［J］. Hum Reprod，2004，19（1）：41-47.doi：10.1093/humrep/deh098http://dx.doi.org/10.1093/humrep/deh098.

Krentowska A，Kowalska I.Metabolic syndrome and its components in different phenotypes of polycystic ovary syndrome［J］.Diabetes Metab Res Rev，2022，38（1）：e3464.doi：10.1002/dmrr.3464http://dx.doi.org/10.1002/dmrr.3464.

Satyaraddi A，Cherian KE，Kapoor N，et al.Body composition，metabolic characteristics，and insulin resistance in obese and nonobese women with polycystic ovary syndrome［J］.J Hum Reprod Sci，2019，12（2）：78-84.doi：10.4103/jhrs.JHRS_2_19http://dx.doi.org/10.4103/jhrs.JHRS_2_19.

Ates S，Sevket O，Sudolmus S，et al.Different phenotypes of polycystic ovary syndrome in Turkish women：clinical and endocrine characteristics［J］.Gynecol Endocrinol，2013，29（10）：931-935.doi：10.3109/09513590.2013.819082http://dx.doi.org/10.3109/09513590.2013.819082.

Dapas M，Lin FTJ，Nadkarni GN，et al.Distinct subtypes of polycystic ovary syndrome with novel genetic associations：an unsupervised， phenotypic clustering analysis［J］.PLoS Med，2020，17（6）：e1003132.doi：10.1371/journal.pmed.1003132http://dx.doi.org/10.1371/journal.pmed.1003132.

Vázquez-Martínez ER，Gómez-Viais YI，García-Gómez E， et al.DNA methylation in the pathogenesis of polycystic ovary syndrome［J］.Reproduction，2019，158（1）：R27-R40. doi：10.1530/REP-18-0449http://dx.doi.org/10.1530/REP-18-0449.

Zhang F，Ma T，Tong X，et al.Electroacupuncture improves metabolic and ovarian function in a rat model of polycystic ovary syndrome by decreasing white adipose tissue， increasing brown adipose tissue， and modulating the gut microbiota［J］.Acupunct Med，2022，40（4）：347-359. doi：10.1177/09645284211056663http://dx.doi.org/10.1177/09645284211056663.

Lan N， Lu Y， Zhang Y， et al.FTO-a common genetic basis for obesity and cancer［J］. Front Genet，2020，11：559138.doi：10.3389/fgene. 2020.559138http://dx.doi.org/10.3389/fgene.2020.559138.

Yin D， Li Y， Liao X，et al.FTO：a critical role in obesity and obesity-related diseases［J］.Br J Nutr，2023，130（10）：1657-1664.doi：10.1017/S0007114523000764http://dx.doi.org/10.1017/S0007114523000764.

Branavan U，Wijesundera S，Chandrasekaran V，et al.In depth analysis of the association of FTO SNP （rs9939609） with the expression of classical phenotype of PCOS：a Sri Lankan study［J］.BMC Med Genet，2020，21（1）：30.doi：10.1186/s12881-020-0961-1http://dx.doi.org/10.1186/s12881-020-0961-1.

Yuan H，Zhu G，Wang F，et al.Interaction between common variants of FTO and MC4R is associated with risk of PCOS［J］.Reprod Biol Endocrinol，2015，13：55.doi：10.1186/s12958-015-0050-zhttp://dx.doi.org/10.1186/s12958-015-0050-z.

Li Y，Han T，Wang Y， et al.Association of Calpain10 polymorphisms with polycystic ovarian syndrome susceptibility：a systematic review and meta-analysis with trial sequential analysis［J］.Front Genet，2023，14：1153960.doi：10.3389/fgene.2023.1153960http://dx.doi.org/10.3389/fgene.2023.1153960.

Dasgupta S，Sirisha PV，Neelaveni K，et al.Association of CAPN10 SNPs and haplotypes with polycystic ovary syndrome among South Indian women［J］.PLoS One，2012，7（2）：e32192.doi：10.1371/journal.pone.0032192http://dx.doi.org/10.1371/journal.pone.0032192.

Praveen VP，Ladjouze A，Sauter KS，et al.Novel CYP19A1 mutations extend the genotype-phenotype correlation and reveal the impact on ovarian function［J］.J Endocr Soc，2020，4（4）：bvaa030.doi：10.1210/jendso/bvaa030http://dx.doi.org/10.1210/jendso/bvaa030.

Joseph S，Barai RS，Bhujbalrao R，et al.PCOSKB：a KnowledgeBase on genes，diseases，ontology terms and biochemical pathways associated with PolyCystic Ovary Syndrome［J］.Nucleic Acids Res，2016，44（D1）：D1032-D1035.doi：10.1093/nar/gkv1146http://dx.doi.org/10.1093/nar/gkv1146.

Heidarzadehpilehrood R，Pirhoushiaran M，Abdollahzadeh R，et al.A review on CYP11A1，CYP17A1，and CYP19A1 polymorphism studies：candidate susceptibility genes for polycystic ovary syndrome（PCOS） and Infertility［J］.Genes （Basel），2022，13（2）：302.doi：10.3390/genes13020302http://dx.doi.org/10.3390/genes13020302.

Liu T，Qin QY，Qu JX， et al. Where are the theca cells from： the mechanism of theca cells derivation and differentiation［J］.Chin Med J （Engl），2020，133 （14）：1711-1718.doi：10.1097/CM9. 0000000000000850http://dx.doi.org/10.1097/CM9.0000000000000850.

Seong SY，Kang MK，Kang H，et al.Low dose rate radiation impairs early follicles in young mice［J］.Reprod Biol，2023，23（4）：100817.doi：10.1016/j.repbio.2023.100817http://dx.doi.org/10.1016/j.repbio.2023.100817.

Yasuda K，Hagiwara E，Takeuchi A， et al.Changes in the distribution of tenascin and fibronectin in the mouse ovary during folliculogenesis， atresia， corpus luteum formation and luteolysis［J］.Zoolog Sci，2005，22（2）：237-245.doi：10.2108/zsj.22.237http://dx.doi.org/10.2108/zsj.22.237.

Whale LJ，Eckery DC，Juengel JL. Determination of steroidogenic potential of ovarian cells of the brushtail possum （Trichosurus vulpecula）［J］.Biol Reprod，2003，69（3）：947-958. doi：10.1095/biolreprod.103.015446http://dx.doi.org/10.1095/biolreprod.103.015446.

Gaasenbeek M，Powell BL，Sovio U，et al.Large-scale analysis of the relationship between CYP11A promoter variation， polycystic ovarian syndrome， and serum testosterone［J］.J Clin Endocrinol Metab，2004，89（5）：2408-2413.doi：10.1210/jc.2003-031640http://dx.doi.org/10.1210/jc.2003-031640.

Piras I，Falchi A，Moral P， et al.Frequencies of promoter pentanucleotide （TTTTA）n of CYP11A gene in European and North African populations［J］.Genet Test，2008，12（1）：93-96. doi：10.1089/gte.2007.0060http://dx.doi.org/10.1089/gte.2007.0060.

Wang Y，Wu X，Cao Y，et al.A microsatellite polymorphism（tttta）n in the promoter of the CYP11a gene in Chinese women with polycystic ovary syndrome［J］.Fertil Steril，2006，86（1）：223-226.doi：10.1016/j.fertnstert.2005.12.037http://dx.doi.org/10.1016/j.fertnstert.2005.12.037.

Sir-Petermann T，Pérez-Bravo F，Angel B，et al.G972R polymorphism of IRS-1 in women with polycystic ovary syndrome［J］.Diabetologia，2001，44 （9）：1200-1201.doi：10.1007/s001250170001http://dx.doi.org/10.1007/s001250170001.

Witchel SF，Aston CE. The role of heterozygosity for CYP21 in the polycystic ovary syndrome［J］.J pediatr endocrinol metabol，2000，13（Suppl 5）：1315-1317.

Biglari-Zadeh G，Sargazi S，Mohammadi M，et al.Relationship between genetic polymorphisms in cell cycle regulatory gene tp53 and polycystic ovarian syndrome：a case-control study and in silico analyses［J］.Biochem Genet，2023，61（5）：1827-1849.doi：10.1007/s10528-023-10349-1http://dx.doi.org/10.1007/s10528-023-10349-1.

Mu L，Ye Z，Hu J，et al.PPM1K-regulated impaired catabolism of branched-chain amino acids orchestrates polycystic ovary syndrome［J］.EBio Medicine，2023，89：104492.doi：10.1016/j.ebiom. 2023.104492http://dx.doi.org/10.1016/j.ebiom.2023.104492.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

多囊卵巢综合征骨骼肌代谢障碍的研究进展

肥胖患者预防及治疗静脉血栓栓塞症抗凝策略的研究进展